Key Takeaway
What to Expect During Telehealth Weight Loss Consultation. Evidence-based answers from FormBlends, a physician-supervised telehealth weight loss clinic.
Here is what the current medical evidence says about what to expect during telehealth weight loss consultation. At FormBlends, our physicians stay on top of the latest research to give patients clear, actionable information. Below we break down what you need to know, based on clinical data and our clinical experience.
What Does the Research Say About What to Expect During Telehealth Weight Loss Consultation?
The medical literature on what to expect during telehealth weight loss consultation provides several key findings:
- GLP-1 receptor agonists work by mimicking natural gut hormones that regulate appetite and blood sugar
- Clinical trials have shown consistent weight loss results across diverse patient populations
- Side effects are primarily gastrointestinal and tend to improve during the first weeks of treatment
- Physician supervision is important for monitoring progress and adjusting dosing
How Does This Apply to Your Treatment?
Knowing what to expect during telehealth weight loss consultation matters because it directly affects treatment decisions. At FormBlends, our physicians consider this information when building your personalized protocol. Every patient is different, and what works for one person may need adjustment for another.
View data table
| Category | Search Volume Share (%) | Detail |
|---|---|---|
| Side Effects | 35 | Nausea, GI issues |
| Cost/Insurance | 28 | Pricing questions |
| Effectiveness | 22 | How much weight loss |
| Eligibility | 15 | BMI requirements |
We recommend discussing what to expect during telehealth weight loss consultation with your FormBlends physician during your consultation. They can explain how it applies to your specific health history and weight loss goals.
Clinical Evidence
GLP-1 medications prescribed through telehealth follow the same dosing protocols used in important trials. Semaglutide starts at 0.25 mg weekly, escalating to 2.4 mg over 16 weeks, as demonstrated in the STEP-1 trial[1] where 1,961 participants lost 14.9% of body weight[1]. Tirzepatide follows a similar escalation from 2.5 mg to 15 mg weekly, with the SURMOUNT-1 trial[2] showing 20.9% weight loss in 2,539 participants[2] over 72 weeks.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →During telehealth consultations, physicians assess contraindications including personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2. Liraglutide 3.0 mg requires more frequent monitoring due to its daily dosing schedule. The SCALE Obesity trial[3] demonstrated 8% weight loss over 56 weeks, making it suitable for patients who prefer daily injections or have insurance coverage limitations for newer weekly formulations.
Clinical Evidence
The STEP and SURMOUNT trials used identical screening criteria to current telehealth protocols, requiring BMI ≥30 or ≥27 with weight-related comorbidities. Telehealth consultations achieve comparable prescription accuracy to in-person visits, with 94% of patients meeting FDA-approved criteria in recent studies.
What Should You Do Next?
If you have questions about what to expect during telehealth weight loss consultation, FormBlends can help. Our licensed physicians provide personalized guidance based on your medical history and goals. Start with a free online evaluation to connect with a provider who can answer your specific questions.
- Semaglutide for weight loss
- Tirzepatide for weight loss
- Compounded GLP-1 medications
Medical References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PubMed | ClinicalTrials.gov | DOI]
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. [PubMed | ClinicalTrials.gov | DOI]
Get Personalized Answers
General information is a starting point, but your treatment should be tailored to you. FormBlends connects you with licensed physicians who can evaluate your situation and provide specific recommendations. Complete your free evaluation today.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →